# Dong-A ST Co., Ltd. clinical trials: 122 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 122 trials with Dong-A ST Co., Ltd. as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dong-A ST Co., Ltd.: 122 rows for $6.10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/dong-a-st-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 122
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 25 newest of 122, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2026 | NCT07686679 | A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia | Dong-A ST Co., Ltd. | Phase 4 | Recruiting | Functional Dyspepsia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686679) |
| June 8, 2026 | NCT07633691 | A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy Adult | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633691) |
| April 7, 2026 | NCT07513649 | A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy Adult Participants | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513649) |
| March 18, 2026 | NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and... | Dong-A ST Co., Ltd. | Phase 1 | Recruiting | Gastric (Stomach) Cancer, GastroEsophageal Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481357) |
| January 15, 2026 | NCT07342062 | Pharmacokinetics and Safety Profiles of DA-1229\_01 in Healthy Subjects at Fed State | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342062) |
| December 22, 2025 | NCT07297940 | Pharmacokinetics and Safety Profiles of DA-1229\_01 in Healthy Subjects at Fasting State | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297940) |
| November 20, 2025 | NCT07239453 | Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Completed | Infective Disorder | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239453) |
| November 20, 2025 | NCT07239440 | Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type... | Dong-A ST Co., Ltd. | Phase 2 | Not yet recruiting | Diabete Mellitus | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239440) |
| November 17, 2025 | NCT07229534 | Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes | Dong-A ST Co., Ltd. | Phase 4 | Not yet recruiting | Diabete Mellitus | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229534) |
| August 24, 2025 | NCT07139886 | A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and... | Dong-A ST Co., Ltd. | Phase 2 | Completed | Acute Gastritis, Chronic Gastritis | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139886) |
| July 1, 2025 | NCT07046715 | Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult... | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046715) |
| June 19, 2025 | NCT07027982 | A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy Adults | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027982) |
| June 6, 2025 | NCT07007533 | A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy Adult | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007533) |
| June 6, 2025 | NCT07007520 | A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Withdrawn | Healthy Adult | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007520) |
| May 28, 2025 | NCT06993181 | Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult... | Dong-A ST Co., Ltd. | Phase 1 | Not yet recruiting | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993181) |
| May 28, 2025 | NCT06993168 | To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects | Dong-A ST Co., Ltd. | Phase 1 | Not yet recruiting | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993168) |
| October 23, 2024 | NCT06654856 | The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Stenosis | Dong-A ST Co., Ltd. | Observational | Completed | Lumbar Spinal Stenosis | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06654856) |
| September 27, 2024 | NCT06616883 | Pharmacokinetics and Safety Profiles After Administration of DA-5221\_01 and Co-administration of 5221\_01-R1 and DA-5221\_01-R2 in Healthy... | Dong-A ST Co., Ltd. | Phase 1 | Unknown | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06616883) |
| April 30, 2024 | NCT06391827 | A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06391827) |
| March 5, 2024 | NCT06293651 | Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in... | Dong-A ST Co., Ltd. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06293651) |
| March 4, 2024 | NCT06290349 | Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have... | Dong-A ST Co., Ltd. | Phase 3 | Active not recruiting | Type 2 Diabetes | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06290349) |
| November 30, 2023 | NCT06151210 | Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis | Dong-A ST Co., Ltd. | Phase 3 | Completed | Gastritis Acute, Gastritis Chronic | 467 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06151210) |
| August 15, 2023 | NCT05992428 | Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05992428) |
| August 14, 2023 | NCT05991401 | Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults | Dong-A ST Co., Ltd. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05991401) |
| July 24, 2023 | NCT05957380 | Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients | Dong-A ST Co., Ltd. | Phase 4 | Completed | Hepatitis B | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05957380) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 67 |
| Phase 1/2 | 2 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 18 |
| Phase 4 | 18 |
| Not applicable | 2 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 93 |
| Unknown | 18 |
| Recruiting | 4 |
| Not yet recruiting | 4 |
| Terminated | 1 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 12 |
| Diabetes Mellitus | 4 |
| Hepatitis B | 3 |
| Urinary Bladder, Overactive | 3 |
| Turner Syndrome | 2 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Dry Eye Syndromes | 2 |
| Alopecia | 2 |
| Pulmonary Arterial Hypertension | 2 |
| Renal Insufficiency | 2 |
| Dwarfism | 1 |
| Osteoporosis, Postmenopausal | 1 |
| Hepatitis B, Chronic | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Peptic Ulcer | 1 |
| Hypertension | 1 |
| Breast Neoplasms | 1 |
| Neutropenia | 1 |
| Parkinson Disease | 1 |
| Diabetic Neuropathies | 1 |
| Infertility | 1 |
| Anovulation | 1 |
| Communicable Diseases | 1 |
| Dyspepsia | 1 |
| Onychomycosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [Media agencies in the United States](https://specstream.ai/data/businesses/media-agencies/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [Pipe suppliers in the United States](https://specstream.ai/data/businesses/pipe-suppliers/united-states)
- [Dental hygiene clinics in the United States](https://specstream.ai/data/businesses/dental-hygiene-clinics/united-states)
- [Siding contractors in the United States](https://specstream.ai/data/businesses/siding-contractors/united-states)
